Background.Although the life expectancy of patients with FL has recently increased, notably since the introduction of rituximab in combination with chemotherapy, little is known regarding the precise causes of patients death. Patients and methods'. This study describes the different causes of death in FL patients among followed since 2000 at Lyon University Hospital, centre Léon Bérard and Mayo Clinic. The causes of death will be classified as related to lymphoma progression, treatment-related toxicity (including TRM and secondary myelodysplastic syndrome/acute myeloid leukemia), secondary neoplasias, or other.

Inclusion Criteria:

• FL patients
• patients recorded as deceased

Exclusion Criteria:

-Other diagnosis than FL

This retrospective analysis was performed in 3 reference center where patients were treated and regularly followed for FL between January 2000 and December 2015. All patients were initially staged according to the conventional recommendations, including a clinical examination and blood tests, a bone marrow biopsy, and a computerized tomography body scan. The treatment modalities have evolved over time and were chosen according to the institutional guidelines.